Immunome
Immunome's revenue fell 23.2% to $7 million in fiscal 2025. Its operating margin was −3,228.8%, up from −3,382.4% a year earlier. Free cash flow was −$201 million. The diluted share count rose 49.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Immunome does
Immunome is a biotechnology company that develops cancer medicines, with a focus on antibody-drug conjugates, or ADCs, which pair an antibody with a drug that attacks the tumor cells it finds. It has not yet sold a product. Its pipeline has three drugs in testing in people and three earlier ones.
Its lead drug, varegacestat, is a once-daily pill for desmoid tumors, which grow in soft tissue. The company reported positive results from a pivotal Phase 3 trial in December 2025, and says it expects to file for approval in the second quarter of 2026. IM-1021 is an ADC under study in a Phase 1 trial in B-cell lymphoma, and IM-3050 is a radioligand therapy aimed at a protein called FAP.
Immunome designs ADCs against new or little-studied targets and has its own drug payload, HC74. It has a history of losses and says it must raise more money to keep developing its drugs.
Its biggest risks, as it describes them
- It has a history of losses and may never be profitable.
- It has not yet filed for approval for a drug or sold one.
- It must raise a lot more money to advance its drugs.
- Its ADC platform may not produce a pipeline of drugs.
- Competitors may develop or sell products faster or more effectively.
Income statement
Immunome lost money in fiscal 2025: a net loss of $212 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 49 | 20 | 138 | 217 | 654 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −1,800.3x | — | — | — | — |
| Current ratio | 5.8x | 3.1x | 6.6x | 4.1x | 14.7x |
| Quick ratio | 5.8x | 3.1x | 6.6x | 4.1x | 14.7x |
Cash flow
Projections
Project Immunome's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 3 insiders bought $2.3 million of Immunome shares on the open market, and 7 insiders sold $27.5 million, $26.0 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Jack HigginsChief Scientific Officer | Sold plan | 13,200 | $25.32 | $334,224 | Form 4 |
| Aug 12, 2026 | Isaac BarchasDirector | Sold plan | 11,048 | $27.25 | $301,058 | Form 4 |
| Aug 11, 2026 | Isaac BarchasDirector | Sold plan | 62,291 | $26.23 | $1.6 million | Form 4 |
| Aug 10, 2026 | Isaac BarchasDirector | Sold plan | 10,125 | $26.07 | $263,959 | Form 4 |
| Aug 7, 2026 | Isaac BarchasDirector | Sold plan | 15,248 | $26.06 | $397,363 | Form 4 |
| Aug 6, 2026 | Isaac BarchasDirector | Sold plan | 20,840 | $26.06 | $543,090 | Form 4 |
| Aug 4, 2026 | Kinney HornChief Business Officer | Sold plan | 90,616 | $25.09 | $2.3 million | Form 4 |
| Jul 7, 2026 | Isaac BarchasDirector | Sold plan | 16,906 | $24.20 | $409,125 | Form 4 |
| Jul 7, 2026 | Kinney HornChief Business Officer | Sold plan | 1,092 | $25.00 | $27,300 | Form 4 |
| Jul 6, 2026 | Isaac BarchasDirector | Sold plan | 83,094 | $24.11 | $2.0 million | Form 4 |
| Jul 2, 2026 | Isaac BarchasDirector | Sold plan | 100,000 | $22.59 | $2.3 million | Form 4 |
| Jul 2, 2026 | Robert LechleiderChief Medical Officer | Sold plan | 55,000 | $22.62 | $1.2 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | −1,340.3% | −2,913.4% |
| Altman Z'' | −0.03 | −7.77 | 13.87 |
| Accruals ratio | −115.0% | −93.7% | −4.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Fail | Fail |
| F-score | — | — | — |
Compare
Put Immunome side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Immunome | FY25 | −23.2% | −3,228.8% | −2,890.1% | — | — | — | |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | 14 | 9 | 7 |
| Revenue growth | — | — | — | — | — | −35.5% | −23.2% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 9 | 8 | 14 | 23 | 23 | 130 | 177 |
| Operating income | −10 | −12 | −25 | −37 | −110 | −306 | −224 |
| Net income | −10 | −18 | −25 | −37 | −107 | −293 | −212 |
| Diluted EPS (US$) | −9.55 | −5.26 | −2.14 | −3.09 | −5.38 | −5.00 | −2.43 |
| Diluted shares (millions) | 1 | 3 | 12 | 12 | 20 | 59 | 87 |
| Cash flow | |||||||
| Cash from operations | −10 | −12 | −18 | −29 | −8 | −111 | −191 |
| Capital expenditure | 0 | 1 | 0 | 0 | 1 | 7 | 10 |
| Free cash flow | −10 | −13 | −18 | −29 | −8 | −118 | −201 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 3 | 5 | 6 | 16 | 26 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 2 | 40 | 49 | 20 | 138 | 217 | 654 |
| Debt incl. finance leases | — | 0 | — | — | — | — | — |
| Total assets | 5 | 44 | 58 | 24 | 148 | 240 | 683 |
| Total liabilities | 2 | 3 | 10 | 7 | 29 | 59 | 49 |
| Shareholders' equity | −36 | 41 | 48 | 17 | 120 | 181 | 634 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −781.4% | −3,382.4% | −3,228.8% |
| Net margin | — | — | — | — | −761.9% | −3,240.4% | −3,060.0% |
| Free cash flow margin | — | — | — | — | −59.9% | −1,304.8% | −2,890.1% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −1,340.3% | −2,913.4% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −624.2% | −55.2% | −113.8% | −156.4% | −194.6% | −52.1% |
| Return on assets | — | −72.0% | −48.2% | −90.0% | −123.8% | −150.7% | −46.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |